Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios

Hoogendoorn, Martine; Feenstra, Talitha; Asukai, Yumi; Borg, Sixten; Hansen, Ryan N.; Jansson, Sven-Arne; Samyshkin, Yevgeniy; Wacker, Margarethe; Briggs, Andrew; Lloyd, Adam; Sullivan, Sean D.; Mölken, Maureen P.M.H. Rutten-van

doi:10.1016/j.jval.2014.03.1721

Cited by 42 publications

(38 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Dutch COPD Model has been cross-validated with other models for hypothetical treatment scenarios8.…”

Section: Discussionmentioning

confidence: 99%

“…We identified 22 such models which used a range of techniques. Three related models scored highly for quality; they were developed by Erasmus University, Rotterdam, and RIVM, Bilthoven, the Netherlands, and cross validated with other models5678. Following contact with the authors we agreed that we could use their most up-to-date “Dutch COPD Model” with English and Scottish data to produce projections for the prevalence, costs and number of deaths from COPD over the period 2011–2030.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Projecting the COPD population and costs in England and Scotland: 2011 to 2030

McLean

Hoogendoorn

Hoogenveen

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

We aimed to estimate the prevalence, healthcare costs and number of deaths among people with chronic obstructive pulmonary disease (COPD) in England and Scotland 2011–2030. We adapted the Dutch COPD Model by using English and Scottish demographic, COPD incidence, COPD prevalence, smoking prevalence and mortality data to make projections. In England, the prevalence of COPD was estimated to be 1.79% (95% uncertainty interval 1.77–1.81) in 2011, increasing to 2.19% (1.85–2.33) by 2030. In Scotland, prevalence was 2.03% (1.96–2.10) in 2011 increasing to 2.20% (1.98–2.40) in 2030. These increases were driven by more women developing COPD. Annual direct healthcare costs of COPD in England were estimated to increase from £1.50 billon (1.18–2.50) in 2011 to £2.32 (1.85–3.08) billion in 2030. In Scotland, costs increased from £159 million (128–268) in 2011 to £207 (165–274) million in 2030. The deaths in England were estimated to increase from 99,200 (92,500–128,500) in 2011, to 129,400 (126,400–133,400) by 2030. In Scotland, in 2011 there were 9,700 (9,000–12,300) deaths and 13,900 (13,400–14,500) deaths in 2030. The number of people with COPD will increase substantially over the coming years in England and Scotland, particularly in females. Services need to adapt to this increasing demand.

show abstract

“…The Dutch COPD Model has been cross-validated with other models for hypothetical treatment scenarios8.…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Projecting the COPD population and costs in England and Scotland: 2011 to 2030

McLean

Hoogendoorn

Hoogenveen

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Six of these nine models also participated in the previous meeting in 2012 [12][13][14][15][16][17]. A short description of these six models can be found in the publication about the proceedings of this second COPD modelling meeting [11]. Three new models also participated.…”

Section: Participating Modelsmentioning

confidence: 99%

“…In 2011 our modelling group took the initiative to establish a network of people involved in COPD modelling around the world (COPD modelling teams, pharmaceutical companies interested in COPD modelling, epidemiologists, clinicians etc). Up to now, we have organized three one-day meetings in 2011,2012 and 2014 with the aim to compare the different available models with respect to model structure and input parameters and to cross validate the models against each other [11]. Proceedings of the third meeting regarding patient heterogeneity are described in the current paper.…”

Section: Introductionmentioning

confidence: 99%

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

et al. 2016

Self Cite

View full text Add to dashboard Cite

Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease (COPD): are current models suitable to evaluate personalized medicine? 3 AbstractObjectives: To assess how suitable current COPD cost-effectiveness models are to evaluate personalized treatment options for COPD by exploring the type of heterogeneity included in current models and by validating outcomes for subgroups of patients.Methods: A consortium of COPD modelling groups completed three tasks. First, they reported all patient characteristics included in the model and provided the level of detail in which the input parameters were specified. Second, groups simulated disease progression, mortality, quality-adjusted life-years (QALYs) and costs for hypothetical subgroups of patients that differed in terms of gender, age, smoking status and lung function (FEV1% predicted). Finally, model outcomes for exacerbations and mortality for subgroups of patients were validated against published subgroup results of two large COPD trials.Results: Nine COPD modelling groups participated. Most models included gender (seven), age (nine), smoking status (six) and FEV1% predicted (nine), mainly to specify disease progression and mortality.Trial results showed higher exacerbation rates for females (found in one model), higher mortality rates for males (two models), lower mortality for younger patients (four models), and higher exacerbation and mortality rates in patients with severe COPD (four models).Conclusions: The majority of currently available COPD cost-effectiveness models are able to evaluate the cost-effectiveness of personalized treatment based on gender, age, smoking and FEV1% predicted. Treatment in COPD is however, more likely to be personalized based on clinical parameters. Two models include several clinical patient characteristics and are therefore most suitable to evaluate personalized treatment, although some important clinical parameters are still missing.4

show abstract

“…In addition, chronic obstructive pulmonary disease (COPD) and pneumonia have been predicted as two of the leading causes of death [1,2]. In addition, the cost of the drugs and pharmaceutical products (DPP) used for the treatment of these diseases has been huge burden on government economies and social security administrations [3,4]. Studies have also reported that chronic diseases pose a threat to public health, and it might not always be possible to access effective treatments due to cost-related factors [5].…”

Section: Introductionmentioning

confidence: 99%

Are treatment guides and rational drug use policies adequately exploited in combating respiratory system diseases?

Doğan¹,

Mutlu²,

Yılmaz³

et al. 2016

Journal of Infection and Public Health

View full text Add to dashboard Cite

The aim of the present study was to increase awareness regarding the rational use of medicines. The data were obtained via the Material Resources Management System Module of the Ministry of Health. For the appropriateness of treatments, the Global Initiative for Asthma, the Global Initiative for Chronic Obstructive Lung Disease, and the guidelines for the rational use of medicines were used. We also investigated whether any de-escalation method or physical exercise was performed. Statistical analyses were performed using descriptive statistics to determine the mean, standard deviation, and frequency. The results showed that healthcare providers ignored potential drug reactions or adverse interactions, and reflecting the lack of adherence to the current treatment guides, 35.8% irrational use of medicines was recorded. Thus, de-escalation methods should be used to decrease costs or narrow the antibiotic spectrum, antibiotic selection should consider the resistance patterns, culturing methods should be analyzed, and monotherapy should be preferred over combination treatments.

show abstract

Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios

Abstract: Mortality was the most important factor determining the differences in cost-effectiveness outcomes between models.

Cited by 42 publications

References 40 publications

Projecting the COPD population and costs in England and Scotland: 2011 to 2030

Projecting the COPD population and costs in England and Scotland: 2011 to 2030

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

Are treatment guides and rational drug use policies adequately exploited in combating respiratory system diseases?

Contact Info

Product

Resources

About